Search results for " PLATELET COUNT"

showing 10 items of 12 documents

Ultrasonography-guided central venous catheterisation in haematological patients with severe thrombocytopenia

2012

BACKGROUND: Cannulation of the internal jugular vein (CVC) is a blind surface landmark-guided technique that could be potentially dangerous in patients with very low platelet counts. In such patients, ultrasonography (US)-guided CVC may be a valid approach. There is a lack of published data on the efficacy and safety of urgent US-guided CVC performed in haematological patients with severe thrombocytopenia. MATERIALS AND METHODS: We retrospectively studied the safety of urgent CVC procedures in haematological patients including those with severe thrombocytopenia (platelet count <30×10(9)/L). From January 1999 to June 2009, 431 CVC insertional procedures in 431 consecutive patients were evalu…

AdultAged 80 and overMaleCatheterization Central VenousAdolescentOriginal ArticlesMiddle AgedSeverity of Illness IndexThrombocytopeniaSettore MED/15 - Malattie Del SangueSettore MED/18 - Chirurgia Generalecentral venous catheterisation ultrasound Seldinger technique low platelet count haematological malignancyHumansFemaleAgedRetrospective StudiesUltrasonography
researchProduct

Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection

2010

Historically, liver biopsy (LB) was the sole method to evaluate the severity of hepatic fibrosis in patients with chronic hepatitis C infection. However, LB is expensive and associated with a risk of severe complications. Therefore, noninvasive tests have been developed to assess the severity of liver fibrosis. The accuracy of Fibroscan (FS) and King's score (KS) was evaluated individually and in combination using liver histology as the reference standard. One hundred and eighty-seven patients were identified who had undergone a biopsy with a diagnosis of chronic hepatitis C virus (HCV) mono-infection (HCV RNA-positive by RT-PCR), attending King's College Hospital (n = 88) or the Royal Free…

AdultLiver CirrhosisMaleKing's scoreHepacivirusPredictive Value of TestsVirologyfibrosis; hepatitis C; King's score; transient elastography; Adult; Alanine Transaminase; Alkaline Phosphatase; Area Under Curve; Aspartate Aminotransferases; Bilirubin; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C Chronic; Histocytochemistry; Humans; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Predictive Value of Tests; Prospective Studies; ROC Curve; gamma-Glutamyltransferase; Hepatology; Infectious Diseases; Virology; Medicine (all)Humansfibrosis hepatitis C King s score transient elastographyAspartate AminotransferasesProspective StudiesChronicHepatologyHistocytochemistryPlatelet CountMedicine (all)fibrosisAlanine TransaminaseBilirubingamma-GlutamyltransferaseHepatitis C ChronicMiddle AgedAlkaline Phosphatasetransient elastographyHepatitis CInfectious DiseasesROC CurveArea Under CurveElasticity Imaging TechniquesFemale
researchProduct

Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study

2017

Background and aims Blood lysosomal acid lipase (LAL) is reduced in non-alcoholic steatohepatitis, which is the major cause of cryptogenic cirrhosis (CC); few data on LAL activity in CC do exist. We investigated LAL activity in a cohort of patients with liver cirrhosis. Methods This is a multicentre cohort study including 274 patients with liver cirrhosis of different aetiology from 19 centres of Internal Medicine, Gastroenterology and Hepatology distributed throughout Italy. Blood LAL activity (nmol/spot/h) was measured with dried blood spot extracts using Lalistat 2. Results Overall, 133 patients had CC, and 141 patients had cirrhosis by other causes (61 viral, 53 alcoholic, 20 alcoholic …

Liver CirrhosisMaleCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; PathogenesisCirrhosisCryptogenic cirrhosisCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Cardiology and Cardiovascular MedicineComorbidityPathogenesisLysosonal acid lipase; non-alcoolic fatty liver disease; cirrhosis030204 cardiovascular system & hematologyGastroenterologyLiver disease0302 clinical medicineModel for End-Stage Liver DiseasePathogenesiRisk FactorsPrevalenceProspective cohort studyMultivariate AnalysiSettore MED/12 - GastroenterologiaMiddle AgedItalyCohortLinear Model030211 gastroenterology & hepatologyFemaleCardiology and Cardiovascular MedicineLiver diseaseHumanmedicine.medical_specialtyLiver CirrhosiDown-Regulation03 medical and health sciencesInternal medicineCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Aged; Biomarkers; Chi-Square Distribution; Comorbidity; Cross-Sectional Studies; Down-Regulation; Dried Blood Spot Testing; Female; Humans; Italy; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Platelet Count; Prevalence; Risk Factors; Sterol EsterasemedicineLysosonal acid lipaseHumansnon-alcoolic fatty liver diseaseAgedCross-Sectional StudieChi-Square Distributionbusiness.industryPlatelet CountcirrhosisRisk FactorBiomarkerCholesterol ester storage diseaseHepatologySterol Esterasemedicine.diseaseCross-Sectional StudiesMultivariate AnalysisLysosomal acid lipaseLinear ModelsDried Blood Spot TestingSteatohepatitisbusinessCryptogenic cirrhosiBiomarkers
researchProduct

Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.

2018

Background & Aims: Baveno VI and expanded Baveno VI criteria can avoid the need for esophagogastroduodenoscopy (EGD) to screen for varices needing treatment (VNT) in a substantial proportion of compensated patients with viral and/or alcoholic cirrhosis. This multicenter, cross-sectional study aims to validate these criteria in patients with compensated cirrhosis due to non-alcoholic fatty liver disease (NAFLD), accounting for possible differences in liver stiffness measurement (LSM) values between M and XL probes. Methods: We assessed 790 patients with NAFLD-related compensated cirrhosis who had EGD within six months of a reliable LSM, measured by FibroScan® using M and/or XL probe. Baveno …

Liver CirrhosisMalemedicine.medical_specialtyAlcoholic liver diseaseCirrhosisVariceEsophageal and Gastric VaricesGastroenterology03 medical and health sciences0302 clinical medicineEsophageal varicesBaveno; Cirrhosis; NAFLD; Stiffness; Varices; Aged; Cross-Sectional Studies; Elasticity Imaging Techniques; Endoscopy Digestive System; Esophageal and Gastric Varices; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Platelet CountNon-alcoholic Fatty Liver DiseaseInternal medicineNAFLDmedicineHumansEndoscopy Digestive SystemBavenoScreening proceduresAgedCirrhosimedicine.diagnostic_testHepatologyEsophagogastroduodenoscopybusiness.industryPlatelet CountFatty liverHepatologyMiddle Agedmedicine.disease3. Good healthCross-Sectional Studies030220 oncology & carcinogenesisStiffneElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleVaricesbusinessJournal of hepatology
researchProduct

Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience

2019

INTRODUCTION: The Baveno VI consensus guidelines and an expanded algorithm suggest that transient elastography (TE) and platelet (PLT) count can be used to identify patients with cirrhosis who can avoid esophagogastroduodenoscopy (EGD). The primary aims of this study were to assess the ability of a simple algorithm, which uses only laboratory parameters, to predict medium/large esophageal varices (EV) in patients with hepatitis C virus (HCV) and cirrhosis from the Rete Sicilia Selezione Terapia-HCV (RESIST-HCV) cohort and to compare the performance of the algorithm with Baveno VI and Expanded Baveno VI criteria. The secondary aim was to assess the role of TE in ruling out large EV. METHODS:…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisBAVENO VI CRITERIA PORTAL-HYPERTENSION CONSENSUS WORKSHOP LIVER STIFFNESS PLATELET COUNT CIRRHOSIS DIAGNOSIS;Esophageal and Gastric Varices03 medical and health sciences0302 clinical medicineRESIST-HCVmedicineesophageal varicesHumansBaveno VIEndoscopy Digestive SystemSerum AlbuminAgedHepatologymedicine.diagnostic_testPlatelet CountEsophagogastroduodenoscopybusiness.industryfungiGastroenterologyReproducibility of Resultsfood and beveragesHepatitis C ChronicMiddle Agedmedicine.diseasetransient elastographyEndoscopyLogistic ModelsCIRRHOSIS PORTAL HYPERTENSION VARICES STIFFNESS030220 oncology & carcinogenesistransient elastography esophageal varices HCV RESIST-HCV Baveno VIMultivariate AnalysisHCVElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyRadiologyGastrointestinal HemorrhagebusinessVaricesTransient elastographyAlgorithms
researchProduct

Regional anticoagulation with heparin of an extracorporeal CO2 removal circuit: a case report

2019

Abstract Background Extracorporeal carbon dioxide removal is an increasingly used respiratory support technique. As is true of all extracorporeal techniques, extracorporeal carbon dioxide removal needs proper anticoagulation. We report a case of a patient at risk of bleeding complications who was treated with extracorporeal carbon dioxide removal and anticoagulated with a regional technique. Case presentation A 56-year-old Caucasian man with a history of chronic obstructive pulmonary disease exacerbation required extracorporeal carbon dioxide removal for severe hypercapnia and acidosis despite mechanical ventilation. The extracorporeal circuit was anticoagulated using a regional heparin tec…

MaleExtracorporeal CirculationLow platelet countExacerbationmedicine.medical_treatment2lcsh:MedicineCase Report030204 cardiovascular system & hematologyExtracorporealExtracorporeal carbon dioxide removal03 medical and health sciencesContinuous venovenous filtrationPulmonary Disease Chronic Obstructive0302 clinical medicineExtracorporeal CO 2 removalExtracorporeal Membrane OxygenationmedicineHeparin regional anticoagulationHumansAcidosisMechanical ventilationbusiness.industryHeparinMedicine (all)removallcsh:RAnticoagulantsExtracorporeal COGeneral MedicineHeparinExtracorporeal CO2 removalCarbon DioxideMiddle AgedRespiration ArtificialTreatment Outcome030220 oncology & carcinogenesisAnesthesiaDisease Progressionmedicine.symptomContinuous venovenous filtration; Extracorporeal CO ; 2; removal ; Heparin regional anticoagulationbusinessHypercapniamedicine.drugJournal of Medical Case Reports
researchProduct

The prognostic value of biological markers in paediatric Hodgkin lymphoma

2015

Abstract Background Many biological and inflammatory markers have been proposed as having a prognostic value at diagnosis of Hodgkin lymphoma (HL), but very few have been validated in paediatric patients. We explored the significance of these markers in a large population of 769 affected children. Patients and methods By using the database of patients enrolled in A.I.E.O.P. (Associazione Italiana di Emato-Oncologia Pediatrica) trial LH2004 for paediatric HL, we identified 769 consecutive patients treated with curative intent from 1st June 2004 to 1st April 2014 with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or hybrid COPP/ABV (cyclophosphamide, vincristine, prednisone, pr…

MaleOncologyCancer ResearchPathologyTime FactorsDatabases Factualmedicine.medical_treatmenthodgkin lymphoma; paediatric; prognostic factorHodgkin lymphoma; Paediatric; Prognostic factor; Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Child; Child Preschool; Databases Factual; Disease Progression; Disease-Free Survival; Female; Ferritins; Hodgkin Disease; Humans; Infant; Infant Newborn; Italy; Kaplan-Meier Estimate; Leukocyte Count; Male; Multivariate Analysis; Neoplasm Staging; Platelet Count; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Blood Platelets; EosinophilsKaplan-Meier EstimateProcarbazineLeukocyte Countchemistry.chemical_compound0302 clinical medicineRisk FactorsPrednisoneAntineoplastic Combined Chemotherapy ProtocolsChildPrognostic factorTumorAge FactorsHodgkin DiseaseVinblastineTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyOncologyPaediatricChild Preschool030220 oncology & carcinogenesisDisease ProgressionFemalemedicine.drugBlood Plateletsmedicine.medical_specialtyVincristineAdolescentDacarbazineBleomycinDisease-Free SurvivalDatabases03 medical and health sciencesPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansPreschoolFactualNeoplasm StagingProportional Hazards ModelsRetrospective StudiesChemotherapyPlatelet Countbusiness.industryInfant NewbornInfantNewbornEosinophilschemistryABVDFerritinsMultivariate AnalysisbusinessBiomarkersHodgkin lymphoma030215 immunologyEuropean Journal of Cancer
researchProduct

Incremental predictive value of mean platelet volume/platelet count ratio in in-hospital stroke after acute myocardial infarction.

2017

IF 2.558; International audience; Stroke is a serious complication after acute myocardial infarction (AMI) and is associated with an increased risk of death. Though the pathophysiological mechanisms are not exactly known, increased inflammation and platelet reactivity could play an important role in the occurrence of stroke during AMI. We aimed to investigate the relationship between both mean platelet volume (MPV), a parameter of platelet function, and C-reactive protein (CRP) and the occurrence of in-hospital ischemic stroke (IHS) after AMI. Data were obtained from a French regional survey for AMI that included 5976 patients admitted to an intensive care unit (ICU) between 2001 and 2010. …

MaleTime FactorsMESH : StrokeMyocardial InfarctionMESH : AgedMESH: ComorbidityComorbidityMESH: Hospitalization030204 cardiovascular system & hematologyMESH : Platelet Countlaw.inventionMESH: Proportional Hazards Models0302 clinical medicineMESH: Aged 80 and overRisk FactorslawMESH: Risk FactorsOdds Ratio[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleMyocardial infarctionMESH : BiomarkersStrokeMESH: Blood PlateletsAged 80 and overMESH: AgedEjection fractionMESH: Middle AgedMESH : PrognosisbiologyMESH : Mean Platelet Volume[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineMiddle AgedPrognosisIntensive care unitstrokeMESH : Risk Factors3. Good healthHospitalizationMESH: Myocardial Infarctionrisk factorplateletsMESH : ComorbidityCardiologyMESH : HospitalizationFemaleMean Platelet VolumeMESH : Time FactorsBlood Plateletsmedicine.medical_specialtyMESH : Male[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAcute myocardial infarctionMESH: PrognosisMESH: StrokeC-reactive protein03 medical and health sciencesInternal medicinemedicineHumansMESH : Middle AgedMESH: Platelet Countcardiovascular diseasesRisk factorMean platelet volumeMESH : Aged 80 and overSurvival analysisAgedProportional Hazards ModelsMESH: HumansPlatelet Countbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyC-reactive proteinMESH: Time FactorsMESH : HumansMESH : Blood Plateletsmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Odds RatioMESH: MaleMESH: Mean Platelet Volumebiology.proteinMESH: BiomarkersMESH : Odds RatioMESH : Myocardial InfarctionbusinessMESH: FemaleBiomarkers030217 neurology & neurosurgery
researchProduct

Splenic marginal zone lymphoma: A prognostic model for clinical use

2006

The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients. The 5-year cause-specific survival (CSS) rate was 76%. In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100 000/μL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006). Values that maintained a negative influence …

Malesplenic marginal zone lymphoma; prognostic factors; International Prognostic Index (IPI)VILLOUS LYMPHOCYTESHydro-LyaseB-CELLLongitudinal StudiePredictive Value of TestInternational Prognostic Index (IPI)BiochemistryGastroenterologyHemoglobinschemistry.chemical_compoundInternational Prognostic IndexRisk FactorsBONE-MARROW INFILTRATION; NON-HODGKINS-LYMPHOMA; C VIRUS-INFECTION; VILLOUS LYMPHOCYTES; B-CELLBONE-MARROW INFILTRATIONAge FactorLongitudinal StudiesMultivariate AnalysiAged 80 and overUnivariate analysisHematologyMortality rateAge FactorsHematologyMiddle AgedPrognosisSplenic NeoplasmSurvival RatePredictive value of testsHumanAdultmedicine.medical_specialtyLymphoma B-CellPrognosiImmunologysplenic marginal zone lymphomaDisease-Free SurvivalPredictive Value of TestsAlbuminsInternal medicineLactate dehydrogenaseAdult; Age Factors; Aged; Aged 80 and over; Albumins; Disease-Free Survival; Hemoglobins; Humans; Hydro-Lyases; Longitudinal Studies; Lymphoma B-Cell; Male; Middle Aged; Multivariate Analysis; Platelet Count; Predictive Value of Tests; Prognosis; Risk Factors; Splenic Neoplasms; Survival Rate; Models Theoretical; HematologymedicineHumansHemoglobinNON-HODGKINS-LYMPHOMASplenic marginal zone lymphomaSurvival rateHydro-LyasesAgedPlatelet Countbusiness.industrySplenic NeoplasmsAlbuminRisk Factorprognostic factorsCell BiologyModels Theoreticalmedicine.diseaseSurgerychemistryMultivariate AnalysisbusinessC VIRUS-INFECTION
researchProduct

Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia

2018

Background: Intravenous immunoglobulin (IVIG) IQYMUNE® is a highly purified 10% IVIG that was assessed using the new stringent definition of response described in the revised guideline on the clinical investigation of IVIG. The efficacy and the safety of IQYMUNE® were investigated in adult patients with chronic primary immune thrombocytopenia (ITP). Methods: In this phase III multinational, multicentre, prospective, uncontrolled, open-label, single-arm study, adult patients with a baseline platelet count < 30 × 10 9 /L were treated with IVIG 10% at a dose of 2 g/kg body weight administered over 2 consecutive days. The primary endpoint was Response over the study period and was defined accor…

medicine.medical_specialtyEuropean Medicines Agency guidelinesPlatelet countRenal functionHigh dose030204 cardiovascular system & hematologyGastroenterology03 medical and health sciencesIntravenous immunoglobulin; High dose; Immune thrombocytopenia; Response; European Medicines Agency guidelines; Platelet count; Bleeding assessment; Infusion rate0302 clinical medicineInfusion rateInternal medicinemedicineClinical endpointPlateletAdverse effectIntravenous immunoglobulinbiologybusiness.industryResponseGuidelineImmune thrombocytopeniaImmune thrombocytopenia030220 oncology & carcinogenesisConcomitantbiology.proteinBleeding assessmentOriginal ArticleAntibodybusinessJournal of Hematology
researchProduct